Overview

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Status:
Not yet recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination. Patients will continue their DMT treatment: metformin or placebo will be used as add-on study treatment.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Antwerp

Collaborators:

AZ Sint-Jan AV
Hasselt University
National MS Center Melsbroek
Noorderhart Pelt
University Hospital, Ghent

Treatments:

Metformin